SEQTOR trial shows comparable PFS for STZ/5-FU followed by everolimus and the reverse sequence in advanced pancreatic NETs.

HONG KONG, Jan. 6, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced that the National Medical Products Administration has approved a significant label update in China for its internally developed, ...

In patients with clear cell renal cell carcinoma (ccRCC), there are a number of second-line options to consider. Sumanta K. Pal, MD, FASCO, professor, Department of Medical Oncology & Therapeutics ...

Investigators sought to describe the patterns of post-progression outcome for patients with HR+/HER2- advanced breast cancer treated with endocrine therapy and a CDK4/6 inhibitor.

Alphamab Oncology (Stock Code: 9966.HK) announced that the results from a phase III clinical study for the treatment of HER2-positive gastric or gastroesophageal junction cancer (GC/GEJ) of ...

Immunotherapy, targeted treatments, HIPEC, and new delivery options ...

The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...

Investigators sought to determine if zanidatamab and chemotherapy, with or without tislelizumab, could extend PFS and OS in patients with untreated locally advanced or metastatic gastroesophageal ...

Investigators compared the efficacy and safety of suvemcitug plus chemotherapy vs chemotherapy plus placebo for patients with platinum-refractory or resistant ovarian cancer.

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival ...

Summit Therapeutics nears a 2026 FDA decision for ivonescimab with $710M cash and Akesobio catalysts. Find out why SMMT stock is upgraded to hold.

In mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkin lymphoma, TP53 mutations are known to affect patients’ prognosis—but questions remain. What does the heterogeneity of TP53 ...